For the quarter ending 2025-10-31, PMCB had $2,227,712 increase in cash & cash equivalents over the period.
| Cash Flow | 2025-10-31 | 2025-07-31 | 2025-04-30 |
|---|---|---|---|
| Asset impaired | - | - | 0 |
| Loss on long term asset | - | - | 0 |
| Non-cash warrant liability | - | - | 469,000 |
| Other non-cash income | - | - | 0 |
| Non-cash interest income | - | - | 300,000 |
| Net income (loss) | -7,417,975 | -8,360,096 | 30,656,050 |
| Gain on related party investment tnf | - | 0 | 21,395,734 |
| Gain on related party investment qcls | 2,089,000 | - | - |
| Adjustment from accrued liabilities to warrant liabilities | -938,000 | 469,000 | - |
| Issuance costs series c preferred stock and warrants | 1,234,553 | - | - |
| Loss on issuance of series c preferred stock | 215,000 | - | - |
| Change in fair value of investment tnf | - | -2,839,000 | 5,063,950 |
| Gain on re-fair value of warrants | 0 | 106,000 | - |
| Change in fair value of warrants - tnf | - | -4,832,000 | -2,367,684 |
| Stock-based compensation | 60,492 | 60,492 | 478,637 |
| Unrealized loss on marketable equity securities | -60,663 | -104,463 | 66,316 |
| Change in fair value of warrant liabilities | -10,474,000 | 243,000 | 10,446,000 |
| Change in fair value of derivative liability | 302,000 | 0 | 2,184,000 |
| Change in fair value of convertible note receivable - femasys | 392,000 | 912,000 | 941,000 |
| Change in fair value of warrant asset femasys | -726,000 | -1,215,000 | -2,091,000 |
| Change in fair value of investment qcls | -5,210,000 | - | - |
| Change in fair value of warrants - qcls | 1,218,000 | - | - |
| Increase in prepaid expenses and other current assets | 264,967 | 14,421 | -36,041 |
| Increase (decrease) in accounts payable | 469,711 | 66,005 | 9,835 |
| Decrease in accrued expenses | -75,000 | -1,006,424 | 1,310,457 |
| Net cash and cash equivalents used in operating activities | -979,523 | -1,993,981 | -2,978,296 |
| Investment in preferred stock and warrants | 3,000,000 | 0 | 7,000,000 |
| Investment convertible note receivable and warrants | - | - | 0 |
| Net cash and cash equivalents used in investing activities | -3,000,000 | 0 | -7,000,000 |
| Proceeds from warrant exercise | - | - | 0 |
| Proceeds from issuance of preferred stock, net of transaction costs | - | - | 0 |
| Repurchase of common stock, net | 0 | 0 | 2,542,276 |
| Redemption of preferred stock | 0 | 0 | 22,486,875 |
| Net proceeds from issuance of series c convertible preferred stock | 6,268,866 | - | - |
| Accrued series c convertible preferred stock and dividends | 61,250 | - | - |
| Net cash and cash equivalents used in financing activities | 6,207,616 | 0 | -25,029,151 |
| Effect of currency rate exchange on cash and cash equivalents | -381 | 123 | -358 |
| Net increase (decrease) in cash and cash equivalents | 2,227,712 | -1,993,858 | -35,007,805 |
| Cash and cash equivalents at beginning of period | 15,172,163 | - | - |
| Cash and cash equivalents at end of period | 15,406,017 | - | - |
PharmaCyte Biotech, Inc. (PMCB)
PharmaCyte Biotech, Inc. (PMCB)